Onno van de Stolpe
Director/Board Member presso Institute For Human Organ & Disease Model Technologies
Profilo
Il Dr. Onno van de Stolpe è amministratore delegato di Galapagos NV. Fa parte del consiglio di amministrazione di Galapagos Biotech Ltd., Institute For Human Organ & Disease Model Technologies e Leyden Laboratories B.V. Il Dr. van de Stolpe è stato precedentemente impiegato come amministratore delegato di Galapagos Genomics NV, amministratore delegato della divisione genomica di Introgene BV, membro del consiglio di sorveglianza di DCPrime BV, manager dello sviluppo aziendale di Mogen International Nv, amministratore delegato di Molecular Probes Europe BV, amministratore delegato di Molecular Probes, Inc. e direttore della Netherlands Foreign Investment Agency. È stato anche membro del consiglio di amministrazione della European Biotech Acquisition Corp. Si è laureato all'Università di Wageningen.
Posizioni attive di Onno van de Stolpe
Società | Posizione | Inizio |
---|---|---|
Institute For Human Organ & Disease Model Technologies | Director/Board Member | - |
Galapagos Biotech Ltd.
Galapagos Biotech Ltd. BiotechnologyHealth Technology Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | - |
Leyden Laboratories B.V.
Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | Director/Board Member | - |
Precedenti posizioni note di Onno van de Stolpe
Società | Posizione | Fine |
---|---|---|
EURO BIOT | Director/Board Member | 28/02/2023 |
GALAPAGOS NV | Founder | 01/04/2022 |
EURO BIOT | Director/Board Member | 15/03/2021 |
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Chief Executive Officer | 02/05/2008 |
Introgene BV | Corporate Officer/Principal | 01/01/1999 |
Formazione di Onno van de Stolpe
Wageningen University | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
GALAPAGOS NV | Health Technology |
Aziende private | 11 |
---|---|
Introgene BV | Health Technology |
Galapagos Biotech Ltd.
Galapagos Biotech Ltd. BiotechnologyHealth Technology Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Mogen International Nv
Mogen International Nv Pharmaceuticals: OtherHealth Technology Part of AstraZeneca PLC, Mogen International Nv is a Dutch company that specializes in medicinal chemicals and botanical products. The private company is based in Leiden, the Netherlands. Mogen International was acquired by Zeneca Group Plc on May 01, 1997 for $74.96 million. | Health Technology |
Molecular Probes, Inc.
Molecular Probes, Inc. BiotechnologyHealth Technology Molecular Probes, Inc. has manufactured fluorescence-based detection solutions for use in labeling molecules for biological research and drug discovery. The company was headquartered in Eugeme, OR. | Health Technology |
Galapagos Genomics NV
Galapagos Genomics NV Pharmaceuticals: MajorHealth Technology Galapagos is a discovery company focused on the identification of disease modifying drug targets by functionally screening human disease models and the subsequent progression of these targets into drug discovery. Galapagos is a genomics based drug discovery company with programs in osteoporosis, rheumatoid arthritis, osteoarthritis, Alzheimer's disease and asthma. | Health Technology |
DCPrime BV
DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Health Technology |
Molecular Probes Europe BV | |
Netherlands Foreign Investment Agency
Netherlands Foreign Investment Agency Financial ConglomeratesFinance Netherlands Foreign Investment Agency provides business investment services. The private company is based in the Netherlands and has no subsidiaries mentioned in the provided metadata. | Finance |
Institute For Human Organ & Disease Model Technologies | |
European Biotech Acquisition Corp.
European Biotech Acquisition Corp. Financial ConglomeratesFinance European Biotech Acquisition Corp. is a blank check company which was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on January 8, 2021 and is headquartered in Lausanne, Switzerland. | Finance |
Leyden Laboratories B.V.
Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | Commercial Services |
- Borsa valori
- Insiders
- Onno van de Stolpe